Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Day One Biopharmaceuticals

    • Home
    • Day One Biopharmaceuticals
Company Deals

Servier to Acquire Day One Biopharmaceuticals for $2.5 Billion – French Pharma Expands U.S. Oncology Presence with ADC Assets

Fineline Cube Mar 9, 2026

Servier Group announced a definitive agreement to acquire Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) for...

Company Deals

Day One Biopharmaceuticals Expands Pipeline with MabCare Therapeutics Licensing Deal

Fineline Cube Jun 19, 2024

Day One Biopharmaceuticals (NASDAQ: DAWN), a California-based biotech company that recently celebrated its first drug...

Recent updates

  • Merck’s Idvynso Gains FDA Approval as Novel Dual-Drug HIV Treatment
  • Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M
  • Roche’s Fenebrutinib Slashes MS Relapse Rates by Over 50% in Phase III Trials
  • Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases
  • Gan & Lee’s Nectin-4 ADC GLR1059 Clears Regulatory Hurdle for Solid Tumor Trials
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Merck’s Idvynso Gains FDA Approval as Novel Dual-Drug HIV Treatment

Company Deals

Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M

Company Drug

Roche’s Fenebrutinib Slashes MS Relapse Rates by Over 50% in Phase III Trials

Company Deals

Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.